Novo Nordisk Likely to Raise Sales Target, Set EBIT at Lower End of Range -- Market Talk

1120 GMT - Danish pharmaceutical giant Novo Nordisk will likely raise its 2024 sales outlook with its 2Q earnings report, but the recently announced DKK5.7 billion impairment will probably mean EBIT g

WSJ13minutes ago

Jefferies Maintains Novo-Nordisk A/S(NVO.US) With Sell Rating, Raises Target Price to $82.5

Jefferies analyst Peter Welford maintains $Novo-Nordisk A/S(NVO.US)$ with a sell rating, and adjusts the target price from $66.75 to $82.5.According to TipRanks data, the analyst has a success rate of

Futu News18:31 · Ratings

Wegovy Outspends TV Advertisers in June Ahead of More Weight-Loss Competition -- WSJ

By Katie Deighton and Megan Graham The weight-loss drug Wegovy has been bombarding TV commercial breaks with ads, more than a year after its manufacturer, Novo Nordisk, limited starter-dose supplies

WSJ18:00

Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock

Analysts' ratings for Novo Nordisk (NYSE:NVO) over the last quarter vary from bullish to bearish, as provided by 8 analysts.

Benzinga00:01

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

BenzingaJul 1 23:17

Novo Nordisk Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 10.43% Cantor Fitzgerald $160 → $160 Reiterates Overweight → Overweight 06/25/2024 12.5% BMO Ca

BenzingaJul 1 23:15